Chimeric Therapeutics Ltd (CHM)

Sydney
0.12
0.00(0.00%)
  • Volume:
    190,523
  • Bid/Ask:
    0.12/0.12
  • Day's Range:
    0.12 - 0.12

CHM Overview

Prev. Close
0.12
Day's Range
0.12-0.12
Revenue
-
Open
0.12
52 wk Range
0.11-0.36
EPS
-0.07
Volume
190,523
Market Cap
48.33M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
867,748
P/E Ratio
-
Beta
-
1-Year Change
-51.18%
Shares Outstanding
420,228,465
Next Earnings Date
-
What is your sentiment on Chimeric Therapeutics?
or
Vote to see community's results!

Chimeric Therapeutics Ltd Company Profile

Chimeric Therapeutics Ltd Company Profile

Employees
0
Market
Australia

Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsNeutralNeutralNeutralSellStrong Sell
SummarySellSellSellStrong SellStrong Sell